antabio logo
  • About Antabio
  • Programs
  • Our team
  • News
  • Jobs
  • Contact
Twitter

FIGHTING

Drug Resistant Infections

Latest news

All news

Marc Lemonnier appointed at the Scientific Advisory Board of JPIAMR

22nd January 2019antabio

ANTABIO Completes € 12.5M Series A

12th July 2018antabio

First publication from Antabio’s novel metallo-β-lactamase (MBL) inhibitor program

23rd March 2018antabio

Metallo ß-lactamase Inhibitor (MBLi)

We develop a novel, safe and efficacious inhibitor of bacterial metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections.

Serine ß-lactamase Inhibitor (SBLi)

We develop a novel serine ß-lactamase inhibitor with excellent coverage against KPC superbugs and best in class potential vs OXA producers including Acinetobacter.

Pseudomonas Elastase Inhibitors (PEi)

A program powered by CARB-X seeking to develop a first-in-class inhibitor of Pseudomonas virulence to be co-administered with standard-of-care antibiotics for the treatment of chronic respiratory infections in Cystic Fibrosis patients.
About Antabio

WHAT WE DO

We are a private biopharmaceutical company developing novel antibacterials targeting drug-resistant pathogens that are deemed a critical priority by the WHO.

Learn more
Follow us

ON TWITTER

Tweets by antabio
Follow us
Legal Notice | © copyright 2017 - Antabio - All rights reserved | Website by KWALT DIGITAL
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok